Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression

Li,Weiyuan; Yang,Dengke; Zhang,Yu; Zhao,Shutian; Li,Dong; Liu,Min

doi:10.3892/or.2020.7742

Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression

Authors:
- Weiyuan Li
- Dengke Yang
- Yu Zhang
- Shutian Zhao
- Dong Li
- Min Liu
View Affiliations

Affiliations: Department of Urology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, P.R. China
Published online on: August 19, 2020 https://doi.org/10.3892/or.2020.7742
Pages: 1985-1996
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is the most common type of renal cancer. Long non‑coding RNA (lncRNA) has been reported to play a vital role in the development and progression of various types of cancer type. However, the underlying molecular mechanisms of PLK1S1 in regulating RCC progression remain unclear. In the present study, PLK1S1 was upregulated in RCC tissues and cells, and PLK1S1 expression was also significantly elevated in stage IV RCC tissues. Kaplan‑Meier analysis showed that patients with high PLK1S1 expression had a shorter overall survival time compared with those with low PLK1S1 expression. Moreover, bioinformatics analysis and luciferase reporter assay demonstrated that PLK1S1 inhibited microRNA (miR)‑653 expression by direct interaction. Functional analyses demonstrated that a miR‑653 inhibitor promoted short hairpin PLK1S1‑attenuated cell proliferation, invasion and sorafenib resistance of RCC cells. In addition, C‑X‑C motif chemokine receptors 5 (CXCR5) was identified as an effector of PLK1S1/miR‑653‑mediated tumorigenesis and drug resistance in RCC cells. Lastly, xenograft experiments demonstrated that PLK1S1 knockdown inhibited tumor growth in vivo. Reverse transcription‑quantitative PCR and western blot analysis revealed that PLK1S1 knockdown upregulated the expression level of miR‑653, whilst downregulating the expression level of CXCR5. In conclusion, the present study revealed that PLK1S1 promoted tumor progression and sorafenib resistance in RCC through regulation of the miR‑653/CXCR5 axis, which may offer a novel treatment strategy for patients with RCC.

View Figures

View References

1	Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P: Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019. View Article : Google Scholar : PubMed/NCBI
2	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
3	Brugarolas J: Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med. 356:185–187. 2007. View Article : Google Scholar : PubMed/NCBI
4	Schmitt AM and Chang HY: Long noncoding RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
5	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
6	Li M, Wang Y, Cheng L, Niu W, Zhao G, Raju JK, Huo J, Wu B, Yin B, Song Y and Bu R: Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications. Oncotarget. 8:48424–48435. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, Lin W, Huang Q, Li G, Zheng J and Chang C: LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ. 24:1502–1517. 2017. View Article : Google Scholar : PubMed/NCBI
8	Huang T, Wang X, Yang X, Ji J, Wang Q, Yue X and Dong Z: Long non-coding RNA DUXAP8 enhances renal cell carcinoma progression via downregulating miR-126. Med Sci Monit. 24:7340–7347. 2018. View Article : Google Scholar : PubMed/NCBI
9	Xu Z, Yang F, Wei D, Liu B, Chen C, Bao Y, Wu Z, Wu D, Tan H, Li J, et al: Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. Oncogene. 36:1965–1977. 2017. View Article : Google Scholar : PubMed/NCBI
10	Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC and Yu J: LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 35:2746–2755. 2016. View Article : Google Scholar : PubMed/NCBI
11	Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, Liang H, Zhao W, Qi L, Guo Z and Gu Y: Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 16:982017. View Article : Google Scholar : PubMed/NCBI
12	Dat Le T, Matsuo T, Yoshimaru T, Kakiuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S and Katagiri T: Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice. Int J Oncol. 40:1455–1469. 2012.PubMed/NCBI
13	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
14	Wang RT, Xu M, Xu CX, Song ZG and Jin H: Decreased expression of miR216a contributes to non-small-cell lung cancer progression. Clin Cancer Res. 20:4705–4516. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang ZZ, Luo YR, Du J, Yu Y, Yang XZ, Cui YJ and Jin XF: MiR-296-5p inhibits cell invasion and migration of esophageal squamous cell carcinoma by downregulating STAT3 signaling. Eur Rev Med Pharmacol Sci. 23:5206–5214. 2019.PubMed/NCBI
16	Han W, Wang L, Zhang L, Wang Y and Li Y: Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/TIAM1 pathways in non-small cell lung cancer. Biochem Biophys Res Commun. 510:462–466. 2019. View Article : Google Scholar : PubMed/NCBI
17	Xie R, Tang J, Zhu X and Jiang H: Silencing of hsa_circ_0004771 inhibits proliferation and induces apoptosis in breast cancer through activation of miR-653 by targeting ZEB2 signaling pathway. Biosci Rep. 39:BSR201819192019. View Article : Google Scholar : PubMed/NCBI
18	Lin CY, Chen YM, Hsu HH, Shiu CT, Kuo HC and Chen TY: Grouper (epinephelus coioides) CXCR4 is expressed in response to pathogens infection and early stage of development. Dev Comp Immunol. 36:112–120. 2012. View Article : Google Scholar : PubMed/NCBI
19	Zhao K, Yao Y, Luo X, Lin B, Huang Y, Zhou Y, Li Z, Guo Q and Lu N: LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer. Carcinogenesis. 39:588–600. 2018. View Article : Google Scholar : PubMed/NCBI
20	Yang J, Tang H, Huang J and An H: Upregulation of CXCR7 is associated with poor prognosis of prostate cancer. Med Sci Monit. 24:5185–5191. 2018. View Article : Google Scholar : PubMed/NCBI
21	Bates RC, DeLeo MJ III and Mercurio AM: The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res. 299:315–324. 2004. View Article : Google Scholar : PubMed/NCBI
22	Zheng Z, Cai Y, Chen H, Chen Z, Zhu D, Zhong Q and Xie W: CXCL13/CXCR5 axis predicts poor prognosis and promotes progression through PI3K/AKT/mTOR pathway in clear cell renal cell carcinoma. Front Oncol. 8:6822018. View Article : Google Scholar : PubMed/NCBI
23	Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G and Novick A: TNM staging of renal cell carcinoma: Workgroup no. 3. Union international contre le cancer (UICC) and the American joint committee on cancer (AJCC). Cancer. 80:992–993. 1997. View Article : Google Scholar : PubMed/NCBI
24	Sobin LH and Fleming ID: TNM classification of malignant tumors, fifth edition (1997). Union internationale contre le cancer and the American joint committee on cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Dong JS, Wu B and Jiang B: LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of renal cell cancer cells by downregulating CDKN1A. Eur Rev Med Pharmacol Sci. 23:10241–10247. 2019.PubMed/NCBI
27	Yue G, Chen C, Bai L, Wang G, Huang Y, Wang Y, Cui H and Xiao Y: Knockdown of long noncoding RNA DLEU1 suppresses the progression of renal cell carcinoma by downregulating the Akt pathway. Mol Med Rep. 20:4551–4557. 2019.PubMed/NCBI
28	Yang Y, Sun DM, Yu JF, Zhang M, Yi C, Yang R, Dan BH and Li AJ: Long noncoding RNA TUG1 promotes renal cell carcinoma cell proliferation, migration and invasion by downregulating microRNA196a. Mol Med Rep. 18:5791–5798. 2018.PubMed/NCBI
29	Shi J, Zhang D, Zhong Z and Zhang W: lncRNA ROR promotes the progression of renal cell carcinoma through the miR-206/VEGF axis. Mol Med Rep. 20:3782–3792. 2019.PubMed/NCBI
30	Yu C and Zhang Y: Characterization of the prognostic values of CXCR family in gastric cancer. Cytokine. 123:1547852019. View Article : Google Scholar : PubMed/NCBI
31	Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, et al: CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 73:571–582. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sun KH, Sun GH, Wu YC, Ko BJ, Hsu HT and Wu ST: TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma. J Cell Mol Med. 20:2020–2028. 2016. View Article : Google Scholar : PubMed/NCBI